Navigation Links
Cephalon Completes Acquisition of Arana Therapeutics
Date:8/10/2009

FRAZER, Pa., Aug. 10 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of all of the outstanding ordinary shares of Australian biotechnology company, Arana Therapeutics Limited. As a result of the acquisition, Arana is now a wholly-owned subsidiary of Cephalon.

Cephalon Chairman and CEO, Frank Baldino Jr., Ph.D., said, "We are excited about the advanced biological and molecular technology expertise that Arana brings to Cephalon. With biologics in inflammatory diseases and clinical candidates in oncology for solid tumors, this acquisition will catalyze the entry of Cephalon into the biologics space."

Cephalon acquires an established protein engineering technology platform to transform proteins, including antibodies, into potent drug candidates. The lead biologic in the portfolio (ART621) is the first domain antibody to enter the clinic targeting TNF alpha, and is in a phase 2 clinical program for rheumatoid arthritis. Additional biologics acquired include: a RANKL inhibitor for bone metastases; one targeting a novel epitope for colorectal cancer in collaboration with Kyowa Hakko-Kirin; one targeting gangliosides for small cell lung cancer and melanoma; one targeting IL 12 /23 for psoriasis and Crohn's disease as well as other earlier stage opportunities.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe.
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... DALLAS , June 29, 2015 ... Type (DNA, RNA, XNA), by Application (Diagnostics, Therapeutics, R&D), by ... Biotechnology & Pharmaceutical Companies, CRO) - Global Forecast to 2020", ... reach $244.93 Million by 2020 from $107.56 Million in 2015, ... market T ables and 67 F ...
(Date:6/29/2015)... Calif. , June 29, 2015   Veracyte, ... company pioneering the field of molecular cytology, today announced ... News Group,s prestigious Top Workplaces list for the second ... Workplace winners based solely on an annual survey of ... and honored that the degree to which Veracyte values ...
(Date:6/29/2015)... 29, 2015 Elsevier , ... products and services, today announced the highlights of its ... 2014 Journal Citation Reports® (JCR) published by Thomson Reuters, ... from 2013 to 2014, ahead of the aggregate across ... rank in 62 subject categories, up from 61 in ...
(Date:6/26/2015)... 26, 2015   Aratana Therapeutics, Inc ... therapeutics company focused on the licensing, development ... companion animals, today announced positive results from ... (AT-002), the company,s innovative therapeutic for appetite ... molecule that mimics ghrelin, the naturally occurring ...
Breaking Biology Technology:Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5
... businesses will receive funding for technology development projects ... Technology Assistance Grant program. , ,The TAG program ... Wisconsin high-tech companies to offset the cost of ... are: Automated Notification Systems, Inc. , Eau ...
... They can cost as much as buildings and there ... the right people are involved and excited, said presenters at ... , ,"User ownership is absolutely essential," said Peter Strombom, CIO ... the application, if they don't feel they're being heard, you're ...
... - The nightmare of managing liability in identity ... of WTN Media's Digital Healthcare Conference, and healthcare providers ... it would be. , ,Using a hypothetical case of ... Michael Best & Friedrich demonstrated how much trouble ...
Cached Biology Technology:Healthcare leaders tell how they rally stakeholders around IT 2Managing the nightmare of identity theft 2Managing the nightmare of identity theft 3Managing the nightmare of identity theft 4
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... Technology have developed a computer program that trains itself ... Fungi which range from yeast to mushrooms ... understanding the recently sequenced fungal genomes can help in ... help to identify potential targets for therapeutic intervention and ...
... out of a scrum herpes virus can cause a skin ... studied the spread of the disease among sumo wrestlers in Japan ... be even more pathogenic, according to an article published in the ... "Scrumpox", or herpes gladiatorum , is a skin infection ...
... has established a National Corrosion Center where researchers will ... that is estimated to cost $276 billion a year ... center, Rice is working closely with NACE International, an ... around the world who are involved in virtually every ...
Cached Biology News:Researchers develop new self-training gene prediction program for fungi 2Researchers develop new self-training gene prediction program for fungi 3Researchers develop new self-training gene prediction program for fungi 4Deadly rugby virus spreads in sumo wrestlers 2Rice University establishes National Corrosion Center 2
... formulated specifically for Alkaline Phosphatase conjugates. ... activity for both the enzyme and the ... This product has been chemically engineered ... a longer shelf life, resistance to various ...
... for arraying proteins of interest with ... equipment. DiscoverLight Protein Array Kits allow ... cell lysate or antibody in a ... specially designed nitrocellulose membranes with a ...
... formulated specifically for Alkaline Phosphatase conjugates. ... activity for both the enzyme and the ... This product has been chemically engineered ... a longer shelf life, resistance to various ...
Request Info...
Biology Products: